Provides An Update On Its NATiV3 Clinical Program Evaluating Lanifibranor In Patients With MASH/NASH
Portfolio Pulse from Benzinga Newsdesk
Inventiva (NASDAQ: IVA) provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment is progressing well with over 80% of the targeted patients enrolled in the main cohort and 100% in the exploratory cohort. The first visit of the last patient is expected in the second half of 2024, with topline results anticipated in mid-2026. The company has also strengthened its patent portfolio and is working on securing financing.
July 05, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva's NATiV3 clinical trial for lanifibranor in MASH/NASH patients is progressing well, with significant patient recruitment and a strengthened patent portfolio. The company is also working on securing financing.
The positive progress in patient recruitment and the strengthened patent portfolio are likely to boost investor confidence. The company's efforts to secure financing further indicate a proactive approach to ensuring the continuity of its activities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100